DK1339678T3 - Selektive agonister til EP4-receptor til behandling af osteoporose - Google Patents

Selektive agonister til EP4-receptor til behandling af osteoporose

Info

Publication number: DK1339678T3
Authority: DK; Denmark
Prior art keywords: osteoporosis; receptor; treatment; selective agonists; agonists
Prior art date: 2000-11-27

Application number

DK01978757T

Other languages

English (en)

Inventor

K Keefe Cameron

Bruce A Lefker

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-27

Filing date

2001-11-05

Publication date

2008-02-04

2001-11-05 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-02-04 Application granted granted Critical

2008-02-04 Publication of DK1339678T3 publication Critical patent/DK1339678T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK01978757T 2000-11-27 2001-11-05 Selektive agonister til EP4-receptor til behandling af osteoporose DK1339678T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25327500P	2000-11-27	2000-11-27
PCT/IB2001/002073 WO2002042268A2 (en)	2000-11-27	2001-11-05	Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (1)

Publication Number	Publication Date
DK1339678T3 true DK1339678T3 (da)	2008-02-04

Family

ID=22959588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01978757T DK1339678T3 (da)	2000-11-27	2001-11-05	Selektive agonister til EP4-receptor til behandling af osteoporose

Country Status (41)

Country	Link
US (3)	US6552067B2 (da)
EP (1)	EP1339678B1 (da)
JP (2)	JP3984164B2 (da)
KR (1)	KR20030053063A (da)
CN (1)	CN1476429A (da)
AR (1)	AR035074A1 (da)
AT (1)	ATE374182T1 (da)
AU (1)	AU2002210848A1 (da)
BG (1)	BG107697A (da)
BR (1)	BR0115687A (da)
CA (1)	CA2429850C (da)
CY (1)	CY1106976T1 (da)
CZ (1)	CZ20031257A3 (da)
DE (1)	DE60130675T2 (da)
DK (1)	DK1339678T3 (da)
EA (1)	EA200300379A1 (da)
EC (1)	ECSP034623A (da)
EE (1)	EE200300246A (da)
ES (1)	ES2291361T3 (da)
GT (2)	GT200100238A (da)
HN (1)	HN2001000266A (da)
HU (1)	HUP0400807A2 (da)
IL (1)	IL155368A0 (da)
IS (1)	IS6775A (da)
MA (1)	MA26961A1 (da)
MX (1)	MXPA03004623A (da)
NO (1)	NO20032360L (da)
NZ (1)	NZ525164A (da)
OA (1)	OA12533A (da)
PA (1)	PA8533901A1 (da)
PE (1)	PE20020637A1 (da)
PL (1)	PL362030A1 (da)
PT (1)	PT1339678E (da)
SI (1)	SI1339678T1 (da)
SK (1)	SK5562003A3 (da)
SV (1)	SV2003000746A (da)
TN (1)	TNSN01166A1 (da)
TW (1)	TW200424170A (da)
UY (1)	UY27038A1 (da)
WO (1)	WO2002042268A2 (da)
ZA (1)	ZA200302803B (da)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ20031257A3 (cs) *	2000-11-27	2004-04-14	Pfizer Products Inc.	Selektivní agonisty receptoru EP4 při léčení osteoporosy
JP4211605B2 (ja) *	2001-07-16	2009-01-21	小野薬品工業株式会社	プロスタノイドアゴニストとしての２ピロリドン誘導体
DE60208568T2 (de) *	2001-07-16	2006-10-05	F. Hoffmann-La Roche Ag	Prostaglandinanaloga als ep4-rezeptoragonisten
PL367740A1 (en) *	2001-07-23	2005-03-07	Ono Pharmaceutical Co, Ltd.	Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
US20040254230A1 (en) *	2001-12-03	2004-12-16	Ogidigben Miller J.	Method for treating ocular hypertension
US7402605B2 (en) *	2002-03-05	2008-07-22	Ono Pharmaceutical Co., Ltd.	8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
EP1490055A1 (en) *	2002-03-18	2004-12-29	Pfizer Products Inc.	Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
CA2478653A1 (en) *	2002-03-18	2003-09-25	Pfizer Products Inc.	Methods of treatment with selective ep4 receptor agonists
US6573294B1 (en)	2002-05-14	2003-06-03	Allergan, Inc.	8-azaprostaglandin analogs as agents for lowering intraocular pressure
ATE487514T1 (de) *	2002-06-06	2010-11-15	Merck Frosst Canada Ltd	1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
JP2005534653A (ja) *	2002-06-06	2005-11-17	メルクフロストカナダアンドカンパニー	眼及び骨疾患の治療に於いてｅｐ４受容体作動薬として使用するための１，５−二置換イミダゾリジン−２−オン誘導体
JP4754820B2 (ja) *	2002-06-10	2011-08-24	メルクセローノソシエテアノニム	プロスタグランジン作動薬としてのγラクタムおよびその使用
GB0219143D0 (en) *	2002-08-16	2002-09-25	Univ Leicester	Modified tailed oligonucleotides
PT1563846E (pt)	2002-10-10	2012-11-13	Ono Pharmaceutical Co	Promotores da produção de factores endógenos de reparação
AU2003275838A1 (en) *	2002-10-25	2004-05-13	Beunard, Jean-Luc	Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7528163B2 (en)	2002-11-08	2009-05-05	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en)	2002-11-08	2007-03-27	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en)	2003-03-26	2006-05-30	Merck & Co. Inc.	EP4 receptor agonist, compositions and methods thereof
PL378342A1 (pl) *	2003-01-10	2006-03-20	F. Hoffmann-La Roche Ag	Pochodne 2-piperydonu jako agoniści prostaglandyn
EP1586564B1 (en) *	2003-01-21	2012-11-28	Ono Pharmaceutical Co., Ltd.	8-azaprostaglandin derivatives and medicinal uses thereof
DE602004013559D1 (de)	2003-03-03	2008-06-19	Serono Lab	G-lactamderivate als prostaglandinagonisten
US6734206B1 (en)	2003-06-02	2004-05-11	Allergan, Inc.	3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en)	2003-06-02	2004-05-11	Allergan, Inc.	8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
WO2005012232A2 (en)	2003-07-18	2005-02-10	Applied Research Systems Ars Holding N.V.	Hydrazide derivatives as prostaglandin receptors modulators
US7034051B2 (en) *	2003-08-28	2006-04-25	Adolor Corporation	Fused bicyclic carboxamide derivatives and methods of their use
CN1845914A (zh)	2003-09-02	2006-10-11	默克公司	用于治疗眼压过高的眼用组合物
WO2005026128A1 (en)	2003-09-04	2005-03-24	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
US7494983B2 (en)	2003-09-04	2009-02-24	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
US20070191319A1 (en) *	2003-12-17	2007-08-16	Pfizer Inc.	Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US7169807B2 (en) *	2004-04-09	2007-01-30	Allergan, Inc.	10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
WO2006020003A2 (en)	2004-07-20	2006-02-23	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
WO2006043655A1 (ja)	2004-10-22	2006-04-27	Ono Pharmaceutical Co., Ltd.	吸入用医薬組成物
JP2008518013A (ja) *	2004-10-26	2008-05-29	アラーガン、インコーポレイテッド	プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
WO2006052630A1 (en) *	2004-11-04	2006-05-18	Allergan, Inc.	Therapeutic substituted piperidone compounds
WO2006052893A2 (en)	2004-11-08	2006-05-18	Allergan, Inc.	Substituted pyrrolidone compounds as ep4 agonists
US7101906B2 (en) *	2004-11-16	2006-09-05	Allergan, Inc.	2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en)	2004-11-23	2007-02-27	Allergan, Inc.	2,3,4-substituted cyclopentanones as therapeutic agents
US7531533B2 (en)	2005-01-27	2009-05-12	Asahi Kasei Pharma Corporation	6-Membered heterocyclic compound and use thereof
AU2006209543B2 (en) *	2005-01-27	2009-04-30	Asahi Kasei Pharma Corporation	Six-membered heterocyclic compound and the use thereof
ATE515263T1 (de) *	2005-05-06	2011-07-15	Allergan Inc	Substituierte beta-lactame und deren verwendung in der medizin
US7772392B2 (en)	2005-05-06	2010-08-10	Allergan, Inc.	Therapeutic substituted β-lactams
US7893107B2 (en) *	2005-11-30	2011-02-22	Allergan, Inc.	Therapeutic methods using prostaglandin EP4 agonist components
KR100598678B1 (ko) *	2006-02-15	2006-07-19	(주)아이앤씨	수직형 대형 폐기물 파쇄기
US20070232660A1 (en) *	2006-04-04	2007-10-04	Allergan, Inc.	Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2008073748A1 (en)	2006-12-08	2008-06-19	University Of Rochester	Expansion of hematopoietic stem cells
WO2008076703A1 (en)	2006-12-18	2008-06-26	Allergan, Inc.	Methods and compositions for treating gastrointestinal disorders
KR20100016299A (ko)	2007-05-08	2010-02-12	고쿠리츠다이가쿠호진 하마마츠이카다이가쿠	Ｅｐ４ 아고니스트를 함유하여 이루어지는 세포 상해성 ｔ 세포의 활성화제
US8198315B2 (en) *	2007-05-23	2012-06-12	Allergan, Inc.	Therapeutic substituted cyclic lactams
US8063033B2 (en) *	2008-01-18	2011-11-22	Allergan, Inc.	Therapeutic beta-lactams
US8202855B2 (en)	2008-03-04	2012-06-19	Allergan, Inc	Substituted beta-lactams
US7705001B2 (en) *	2008-03-18	2010-04-27	Allergan, Inc	Therapeutic substituted gamma lactams
EP2320906B1 (en) *	2008-08-14	2016-02-24	Beta Pharma Canada Inc.	Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010116270A1 (en)	2009-04-10	2010-10-14	Pfizer Inc.	Ep2/4 agonists
US20120190637A1 (en)	2009-10-14	2012-07-26	Gemmus Pharma, Inc.	Combination therapy treatment for viral infections
WO2011111714A1 (ja) *	2010-03-08	2011-09-15	科研製薬株式会社	新規なｅｐ４アゴニスト
CA2738045C (en)	2010-05-28	2019-02-19	Simon Fraser University	Conjugate compounds, methods of making same, and uses thereof
EP2397141A1 (en) *	2010-06-16	2011-12-21	LEK Pharmaceuticals d.d.	Process for the synthesis of beta-amino acids and derivatives thereof
US8697057B2 (en)	2010-08-19	2014-04-15	Allergan, Inc.	Compositions and soft tissue replacement methods
CA2827615A1 (en)	2011-02-17	2012-08-23	Dennis E. Van Epps	Compositions and improved soft tissue replacement methods
EP2678022A2 (en)	2011-02-23	2014-01-01	Allergan, Inc.	Compositions and improved soft tissue replacement methods
WO2013123275A1 (en)	2012-02-16	2013-08-22	Allergan, Inc.	Compositions and improved soft tissue replacement methods
EP2814482A1 (en)	2012-02-16	2014-12-24	Allergan, Inc.	Compositions and improved soft tissue replacement methods
WO2013123274A1 (en)	2012-02-16	2013-08-22	Allergan, Inc.	Compositions and improved soft tissue replacement methods
WO2013123272A1 (en)	2012-02-16	2013-08-22	Allergan, Inc.	Compositions and improved soft tissue replacement methods
CN104640542B (zh)	2012-07-19	2017-09-22	开曼化学股份有限公司	用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物
ES2733998T3 (es)	2012-10-29	2019-12-03	Cardio Incorporated	Agente terapéutico específico de enfermedad pulmonar
WO2014144584A2 (en) *	2013-03-15	2014-09-18	Cayman Chemical Company, Inc.	Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
JP6368351B2 (ja)	2013-03-15	2018-08-01	ケイマンケミカルカンパニー，インコーポレーテッド	ジフルオロラクタムアナログを合成する方法
WO2014144610A1 (en)	2013-03-15	2014-09-18	Cayman Chemical Company, Inc.	Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
US10729810B2 (en)	2013-07-19	2020-08-04	Cayman Chemical Company, Inc	Methods, systems, and compositions for promoting bone growth
IL280864B2 (en)	2013-08-09	2024-03-01	Ardelyx Inc	Compounds and methods for inhibiting phosphate transport
WO2015056504A1 (ja)	2013-10-15	2015-04-23	小野薬品工業株式会社	薬剤溶出性ステントグラフト
US9650414B1 (en)	2014-05-30	2017-05-16	Simon Fraser University	Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
JP6588475B2 (ja)	2014-06-06	2019-10-09	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	治療用化合物としての新規のｅｐ４アゴニスト
US9540357B1 (en)	2014-07-31	2017-01-10	Allergan, Inc.	15-aryl prostaglandins as EP4 agonists, and methods of use thereof
US10400000B2 (en)	2015-06-12	2019-09-03	Simon Fraser University	Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof
CN107011377B (zh) *	2017-05-03	2019-02-26	南通书创药业科技有限公司	一种β-羰基磷酸酯的制备方法
PL3733665T3 (pl) *	2017-12-25	2023-02-06	Asahi Kasei Pharma Corporation	Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4
EP3972599A1 (en)	2019-05-21	2022-03-30	Ardelyx, Inc.	Combination for lowering serum phosphate in a patient

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1158163A (en)	1966-06-15	1969-07-16	Berk Ltd	Improvements in or relating to Polymer Compositions
ZA72645B (en) *	1971-03-05	1972-11-29	Upjohn Co	Prostaglandin analogs
DE2346706A1 (de) *	1973-09-17	1975-04-03	Hoechst Ag	Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung
US3975399A (en)	1974-08-06	1976-08-17	E. I. Du Pont De Nemours And Company	1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
US4113873A (en)	1975-04-26	1978-09-12	Tanabe Seiyaku Co. Ltd.	8-azaprostanoic acid derivatives
NL7604330A (nl)	1975-04-28	1976-11-01	Syntex Inc	Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten.
DE2528664A1 (de)	1975-06-27	1977-01-13	Hoechst Ag	Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en)	1976-03-31	1979-11-30	Labaz	8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de)	1976-05-04	1977-11-17	Hoechst Ag	Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) *	1976-08-06	1979-12-04	Pfizer Inc.	1,5-Disubstituted-2-pyrrolidones
CA1077948A (en) *	1976-08-06	1980-05-20	Albin J. Nelson	1,-5 disubstituted-2-pyrrolidones and processes for their production
US4320136A (en)	1980-08-11	1982-03-16	E. I. Du Pont De Nemours And Company	8-Aza-16,16-difluoroprostanoids
US4456613A (en)	1982-12-27	1984-06-26	E. I. Du Pont De Nemours And Company	6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
TW288010B (da)	1992-03-05	1996-10-11	Pfizer
SE9302334D0 (sv)	1993-07-06	1993-07-06	Ab Astra	New compounds
ZA944647B (en)	1993-07-06	1995-01-06	Astra Ab	Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives
IL113112A (en)	1994-03-28	2000-06-01	Nissan Chemical Ind Ltd	Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them
US5955481A (en)	1994-03-28	1999-09-21	Nissan Chemical Industries, Ltd.	Pyridine type thiazolidines
US5703108A (en) *	1996-02-28	1997-12-30	Pfizer Inc.	Bone deposition by certain prostaglandin agonists
AU6427599A (en) *	1998-10-15	2000-05-01	Merck & Co., Inc.	Methods for stimulating bone formation
AU1444200A (en)	1998-10-15	2000-05-01	Merck & Co., Inc.	Methods for inhibiting bone resorption
CZ20022048A3 (cs) *	1999-12-22	2004-03-17	Pfizer Products Inc.	Selektivní agonisty receptoru EP4 při léčení osteoporosy
EP1132086B1 (en) *	2000-01-31	2006-05-31	Pfizer Products Inc.	Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure
US20010056060A1 (en) *	2000-02-07	2001-12-27	Cameron Kimberly O.	Treatment of osteoporsis with EP2/EP4 receptor selective agonists
CZ20031257A3 (cs) *	2000-11-27	2004-04-14	Pfizer Products Inc.	Selektivní agonisty receptoru EP4 při léčení osteoporosy
US6573294B1 (en) *	2002-05-14	2003-06-03	Allergan, Inc.	8-azaprostaglandin analogs as agents for lowering intraocular pressure

2001
- 2001-11-05 CZ CZ20031257A patent/CZ20031257A3/cs unknown
- 2001-11-05 EP EP01978757A patent/EP1339678B1/en not_active Expired - Lifetime
- 2001-11-05 PT PT01978757T patent/PT1339678E/pt unknown
- 2001-11-05 ES ES01978757T patent/ES2291361T3/es not_active Expired - Lifetime
- 2001-11-05 EE EEP200300246A patent/EE200300246A/xx unknown
- 2001-11-05 DE DE60130675T patent/DE60130675T2/de not_active Expired - Fee Related
- 2001-11-05 EA EA200300379A patent/EA200300379A1/ru unknown
- 2001-11-05 HU HU0400807A patent/HUP0400807A2/hu unknown
- 2001-11-05 SK SK556-2003A patent/SK5562003A3/sk not_active Application Discontinuation
- 2001-11-05 NZ NZ525164A patent/NZ525164A/en unknown
- 2001-11-05 AU AU2002210848A patent/AU2002210848A1/en not_active Abandoned
- 2001-11-05 CA CA002429850A patent/CA2429850C/en not_active Expired - Fee Related
- 2001-11-05 SI SI200130776T patent/SI1339678T1/sl unknown
- 2001-11-05 DK DK01978757T patent/DK1339678T3/da active
- 2001-11-05 AT AT01978757T patent/ATE374182T1/de not_active IP Right Cessation
- 2001-11-05 WO PCT/IB2001/002073 patent/WO2002042268A2/en active IP Right Grant
- 2001-11-05 JP JP2002544404A patent/JP3984164B2/ja not_active Expired - Lifetime
- 2001-11-05 CN CNA018194877A patent/CN1476429A/zh active Pending
- 2001-11-05 PL PL01362030A patent/PL362030A1/xx not_active Application Discontinuation
- 2001-11-05 MX MXPA03004623A patent/MXPA03004623A/es active IP Right Grant
- 2001-11-05 IL IL15536801A patent/IL155368A0/xx unknown
- 2001-11-05 KR KR10-2003-7007109A patent/KR20030053063A/ko not_active Application Discontinuation
- 2001-11-05 BR BR0115687-0A patent/BR0115687A/pt not_active Withdrawn
- 2001-11-05 OA OA1200300141A patent/OA12533A/en unknown
- 2001-11-21 US US09/990,556 patent/US6552067B2/en not_active Expired - Fee Related
- 2001-11-23 HN HN2001000266A patent/HN2001000266A/es unknown
- 2001-11-23 UY UY27038A patent/UY27038A1/es not_active Application Discontinuation
- 2001-11-26 TW TW093115078A patent/TW200424170A/zh unknown
- 2001-11-26 PE PE2001001180A patent/PE20020637A1/es not_active Application Discontinuation
- 2001-11-26 TN TNTNSN01166A patent/TNSN01166A1/fr unknown
- 2001-11-26 SV SV2001000746A patent/SV2003000746A/es unknown
- 2001-11-26 AR ARP010105489A patent/AR035074A1/es unknown
- 2001-11-27 GT GT200100238A patent/GT200100238A/es unknown
- 2001-11-27 GT GT200100238AK patent/GT200100238AA/es unknown
- 2001-11-27 PA PA20018533901A patent/PA8533901A1/es unknown
2002
- 2002-12-20 US US10/326,366 patent/US6747054B2/en not_active Expired - Fee Related
2003
- 2003-04-03 BG BG107697A patent/BG107697A/xx unknown
- 2003-04-10 ZA ZA200302803A patent/ZA200302803B/en unknown
- 2003-04-10 IS IS6775A patent/IS6775A/is unknown
- 2003-05-13 MA MA27159A patent/MA26961A1/fr unknown
- 2003-05-26 NO NO20032360A patent/NO20032360L/no not_active Application Discontinuation
- 2003-05-27 EC EC2003004623A patent/ECSP034623A/es unknown
- 2003-09-23 US US10/668,633 patent/US7192979B2/en not_active Expired - Fee Related
2007
- 2007-05-11 JP JP2007127062A patent/JP2007197467A/ja active Pending
- 2007-11-06 CY CY20071101420T patent/CY1106976T1/el unknown

Also Published As

Publication number	Publication date
WO2002042268A2 (en)	2002-05-30
CZ20031257A3 (cs)	2004-04-14
CY1106976T1 (el)	2012-09-26
IL155368A0 (en)	2003-11-23
EP1339678A2 (en)	2003-09-03
SV2003000746A (es)	2003-01-13
EE200300246A (et)	2003-10-15
TW200424170A (en)	2004-11-16
TNSN01166A1 (fr)	2005-11-10
ZA200302803B (en)	2004-04-13
WO2002042268A3 (en)	2002-07-25
NO20032360L (no)	2003-07-23
ECSP034623A (es)	2003-07-25
SK5562003A3 (en)	2004-08-03
NO20032360D0 (no)	2003-05-26
PA8533901A1 (es)	2002-11-28
JP3984164B2 (ja)	2007-10-03
HUP0400807A2 (hu)	2004-07-28
PE20020637A1 (es)	2002-07-18
EA200300379A1 (ru)	2003-08-28
US20030149086A1 (en)	2003-08-07
UY27038A1 (es)	2002-07-31
PT1339678E (pt)	2007-11-30
AR035074A1 (es)	2004-04-14
US20020065308A1 (en)	2002-05-30
IS6775A (is)	2003-04-10
DE60130675D1 (de)	2007-11-08
CA2429850A1 (en)	2002-05-30
NZ525164A (en)	2005-04-29
JP2004521869A (ja)	2004-07-22
PL362030A1 (en)	2004-10-18
SI1339678T1 (sl)	2007-12-31
BG107697A (en)	2004-01-30
DE60130675T2 (de)	2008-01-24
US20040259921A1 (en)	2004-12-23
HN2001000266A (es)	2002-01-30
GT200100238AA (es)	2004-05-12
CA2429850C (en)	2008-12-30
MXPA03004623A (es)	2003-09-05
GT200100238A (es)	2002-06-26
ATE374182T1 (de)	2007-10-15
AU2002210848A1 (en)	2002-06-03
BR0115687A (pt)	2003-09-09
MA26961A1 (fr)	2004-12-20
CN1476429A (zh)	2004-02-18
US7192979B2 (en)	2007-03-20
JP2007197467A (ja)	2007-08-09
US6747054B2 (en)	2004-06-08
EP1339678B1 (en)	2007-09-26
KR20030053063A (ko)	2003-06-27
ES2291361T3 (es)	2008-03-01
US6552067B2 (en)	2003-04-22
OA12533A (en)	2006-06-05

Publication	Publication Date	Title
DK1339678T3 (da)	2008-02-04	Selektive agonister til EP4-receptor til behandling af osteoporose
EE200200355A (et)	2003-10-15	EP4 retseptori selektiivsed agonistid osteoporoosi raviks
IS6785A (is)	2003-04-14	EP4 viðtakahindrar til meðhöndlunar á liðagigt
CY2017020I1 (el)	2017-11-14	Στεροειδη ως αγωνιστες για τους υποδοχεις fxr
DK1446379T3 (da)	2009-07-27	Arylanilin-beta2-adrenergiske receptoragonister
NO20023672D0 (no)	2002-08-02	Sammensetninger for kontrollert frigivelse
DK1296935T3 (da)	2009-06-22	Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1553929T3 (da)	2013-05-13	Sammensætning med kontrolleret frigivelse.
NO20030471D0 (no)	2003-01-30	Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
DK1200073T3 (da)	2007-05-07	Selektive iGluR5-receptorantagonister til behandling af migræne
DK1201655T3 (da)	2005-11-28	Fremgangsmåde til fremstilling af non-steroide glucocorticoidreceptormodulatorer
DK1392318T3 (da)	2007-06-25	15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1142477T3 (da)	2004-10-11	Sammensætninger med reguleret frigivelse
DK2189162T3 (da)	2014-02-03	Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1225878T3 (da)	2007-03-05	RAR-gamma-selektive retinoidagonister til behandling af emfysem
ITMI20001699A0 (it)	2000-07-25	Agente coesivizzante inorganico per impasti cementizi autocompattanti
DK1268482T3 (da)	2003-12-22	Pyranoindoler til behandling af glaukom
DK1309607T3 (da)	2005-01-17	Fremgangsmåde til fremstilling af LHRH-antagonister
DK1281707T3 (da)	2005-05-02	Fremgangsmåde til fremstilling af 5-substituerede isobenzenfuraner
DK1451177T3 (da)	2007-07-02	Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne
ITMO20030065A0 (it)	2003-03-13	Dispositivo per l'ancoraggio di lastre ceramiche.
NO20022142L (no)	2002-05-03	Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
ES1049390Y (es)	2002-04-16	Dispositivo de anclaje para encofrados de hormigon.
DK1099490T3 (da)	2004-03-29	Indretning til afkapning af rør
ES1049092Y (es)	2002-03-16	Dispositivo de alineacion para encofrados de hormigon.